Expert panel backs continued use of 3 asthma drugs

An expert panel assembled by the FDA has recommended that three asthma drugs -- Advair, Serevent, and Foradil -- remain on the market with an adjustment in warning labels. The panel concluded that despite evidence that the drugs are linked to a small increase in the number of patient deaths, the benefits exceed the risks. The FDA will consider the recommendation and make a final ruling.

- read this report from KIDK TV for more

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.